Reportable Segment — Interest Expense
Business Segments · Interest ExpenseEli Lilly Reportable Segment — Interest Expense decreased by 27.9% to $179.60M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.8%, from $192.70M to $179.60M. Over 2 years (FY 2022 to FY 2024), Reportable Segment — Interest Expense shows an upward trend with a 53.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ1 2022
Last reportedQ3 2025
Rolls up toInterest Expense
How to read this metric
An increase may indicate higher debt levels or rising interest rates, potentially reducing segment profitability.
Detailed definition
Represents the cost incurred by the reportable segment for borrowed funds used to finance operations or capital projects...
Peer comparison
Standard across pharmaceutical peers, though often allocated based on internal capital charges.
Metric ID:
lly_segment_reportable_segment_interest_expenseHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $82.90M | $82.90M | $82.90M | $82.90M | $121.48M | $121.48M | $121.48M | $121.48M | $179.60M | $183.60M | $192.70M | $224.70M | $243.70M | $249.00M | $179.60M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +46.5% | +0.0% | +0.0% | +0.0% | +47.8% | +2.2% | +5.0% | +16.6% | +8.5% | +2.2% | -27.9% |
| YoY Change | — | — | — | — | +46.5% | +46.5% | +46.5% | +46.5% | +47.8% | +51.1% | +58.6% | +85.0% | +35.7% | +35.6% | -6.8% |
Range$82.90M – $249.00M
CAGR+24.7%
Avg YoY Growth+44.8%
Median YoY Growth+46.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — interest expense?
- Eli Lilly (LLY) reported reportable segment — interest expense of $179.60M in Q3 2025.
- How has Eli Lilly's reportable segment — interest expense changed year-over-year?
- Eli Lilly's reportable segment — interest expense decreased by 6.8% year-over-year, from $192.70M to $179.60M.
- What is the long-term trend for Eli Lilly's reportable segment — interest expense?
- Over 2 years (2022 to 2024), Eli Lilly's reportable segment — interest expense has grown at a 53.4% compound annual growth rate (CAGR), from $331.60M to $780.60M.
- What does reportable segment — interest expense mean?
- The cost of interest paid on debt allocated to this specific business segment.